Translational research - the point at which general scientific knowledge starts to be applied to addressing a specific disease or condition - is the first step on the path to developing a new drug. But traditional investors in translational research (large- and medium-cap biopharmaceutical companies and life science-focused venture capital funds) are becoming increasingly risk averse in the face of escalating challenges in the drug development process. FasterCures recently hosted a Financial Innovations Lab to examine business models and financial instruments that can improve the risk/return ratio for early-stage investors. In this session you'll hear from experts who have designed and implemented new models like leveraged funds, research-based obligations and collaborative funding. If we can find a way to close the funding gap for translational research, we can get one step closer to urgently needed treatments.
Like a contemporary "whodunit" with a global crime scene, the financial meltdown has left behind countless victims, and lots of pointing fingers. The reasons for the collapse are debated by this group of estimable economists, some of whom worry that without really understanding what happened, we are in for a repeat episode.